nodes	percent_of_prediction	percent_of_DWPC	metapath
Mefenamic acid—CYP2C8—Tazarotene—psoriasis	0.128	0.201	CbGbCtD
Mefenamic acid—PTGS2—Triamcinolone—psoriasis	0.0971	0.153	CbGbCtD
Mefenamic acid—PTGS2—Betamethasone—psoriasis	0.0834	0.131	CbGbCtD
Mefenamic acid—CYP2C8—Cholecalciferol—psoriasis	0.0546	0.0859	CbGbCtD
Mefenamic acid—PTGS2—Dexamethasone—psoriasis	0.0485	0.0762	CbGbCtD
Mefenamic acid—CYP2C8—Mycophenolate mofetil—psoriasis	0.0473	0.0744	CbGbCtD
Mefenamic acid—CYP2C9—Cholecalciferol—psoriasis	0.0381	0.0599	CbGbCtD
Mefenamic acid—CYP2C8—Hydrocortisone—psoriasis	0.038	0.0597	CbGbCtD
Mefenamic acid—CYP2C8—Cyclosporine—psoriasis	0.0359	0.0564	CbGbCtD
Mefenamic acid—CYP2C9—Cyclosporine—psoriasis	0.025	0.0394	CbGbCtD
Mefenamic acid—CYP2C8—Dexamethasone—psoriasis	0.0236	0.0372	CbGbCtD
Mefenamic acid—CYP2C9—Dexamethasone—psoriasis	0.0165	0.0259	CbGbCtD
Mefenamic acid—Acetylsalicylic acid—NFKBIA—psoriasis	0.00474	0.539	CrCbGaD
Mefenamic acid—Acetylsalicylic acid—TP53—psoriasis	0.0021	0.239	CrCbGaD
Mefenamic acid—CYP2C8—CYP2E1 reactions—CYP2S1—psoriasis	0.00179	0.0656	CbGpPWpGaD
Mefenamic acid—CYP2C9—CYP2E1 reactions—CYP2S1—psoriasis	0.00146	0.0534	CbGpPWpGaD
Mefenamic acid—AKR1C2—Metapathway biotransformation—CYP2S1—psoriasis	0.00141	0.0516	CbGpPWpGaD
Mefenamic acid—PTGS2—Fluocinonide—Clobetasol propionate—psoriasis	0.00124	0.157	CbGdCrCtD
Mefenamic acid—CYP2C8—Xenobiotics—CYP2S1—psoriasis	0.00111	0.0407	CbGpPWpGaD
Mefenamic acid—Diclofenac—CXCL8—psoriasis	0.00104	0.118	CrCbGaD
Mefenamic acid—AKR1C1—Metapathway biotransformation—CYP2S1—psoriasis	0.00104	0.0379	CbGpPWpGaD
Mefenamic acid—PTGS2—Fluocinonide—Beclomethasone—psoriasis	0.000995	0.126	CbGdCrCtD
Mefenamic acid—PTGS2—Fluocinonide—Fluocinolone Acetonide—psoriasis	0.000967	0.122	CbGdCrCtD
Mefenamic acid—Ketoprofen—CXCL8—psoriasis	0.000919	0.104	CrCbGaD
Mefenamic acid—CYP2C9—Xenobiotics—CYP2S1—psoriasis	0.000905	0.0331	CbGpPWpGaD
Mefenamic acid—AKR1C1—Retinoid metabolism and transport—APOE—psoriasis	0.000772	0.0282	CbGpPWpGaD
Mefenamic acid—PTGS2—Fluticasone Propionate—Clobetasol propionate—psoriasis	0.00075	0.0948	CbGdCrCtD
Mefenamic acid—AKR1C3—Metapathway biotransformation—CYP2S1—psoriasis	0.000697	0.0255	CbGpPWpGaD
Mefenamic acid—PTGS2—Fluticasone Propionate—Beclomethasone—psoriasis	0.0006	0.076	CbGdCrCtD
Mefenamic acid—PTGS2—Fluticasone Propionate—Fluocinonide—psoriasis	0.0006	0.076	CbGdCrCtD
Mefenamic acid—PTGS2—Fluticasone Propionate—Fluocinolone Acetonide—psoriasis	0.000584	0.0738	CbGdCrCtD
Mefenamic acid—PTGS1—Phase 1 - Functionalization of compounds—CYP2S1—psoriasis	0.000579	0.0212	CbGpPWpGaD
Mefenamic acid—AKR1C3—Retinoid metabolism and transport—APOE—psoriasis	0.00052	0.019	CbGpPWpGaD
Mefenamic acid—CYP2C8—Cytochrome P450 - arranged by substrate type—CYP2S1—psoriasis	0.000462	0.0169	CbGpPWpGaD
Mefenamic acid—CYP2C8—Oxidation by Cytochrome P450—CYP2S1—psoriasis	0.000455	0.0167	CbGpPWpGaD
Mefenamic acid—PTGS2—Fluocinonide—Dexamethasone—psoriasis	0.000454	0.0574	CbGdCrCtD
Mefenamic acid—PTGS2—Fluocinonide—Betamethasone—psoriasis	0.000454	0.0574	CbGdCrCtD
Mefenamic acid—PTGS2—Fluocinonide—Triamcinolone—psoriasis	0.000443	0.0561	CbGdCrCtD
Mefenamic acid—PTGS1—Overview of nanoparticle effects—CRP—psoriasis	0.000428	0.0156	CbGpPWpGaD
Mefenamic acid—AKR1C1—Diseases associated with visual transduction—APOE—psoriasis	0.000394	0.0144	CbGpPWpGaD
Mefenamic acid—CYP2C9—Cytochrome P450 - arranged by substrate type—CYP2S1—psoriasis	0.000376	0.0137	CbGpPWpGaD
Mefenamic acid—CYP2C8—Phase 1 - Functionalization of compounds—CYP2S1—psoriasis	0.000374	0.0137	CbGpPWpGaD
Mefenamic acid—CYP2C9—Oxidation by Cytochrome P450—CYP2S1—psoriasis	0.000371	0.0136	CbGpPWpGaD
Mefenamic acid—PTGS2—Quercetin and Nf-kB/ AP-1 Induced Cell Apoptosis—NFKBIA—psoriasis	0.000355	0.013	CbGpPWpGaD
Mefenamic acid—PTGS2—Overview of nanoparticle effects—CRP—psoriasis	0.000339	0.0124	CbGpPWpGaD
Mefenamic acid—PTGS1—Biological oxidations—CYP2S1—psoriasis	0.000308	0.0113	CbGpPWpGaD
Mefenamic acid—CYP2C9—Phase 1 - Functionalization of compounds—CYP2S1—psoriasis	0.000304	0.0111	CbGpPWpGaD
Mefenamic acid—AKR1C2—Metabolism—NDUFA5—psoriasis	0.000288	0.0105	CbGpPWpGaD
Mefenamic acid—PTGS2—Calcium signaling in the CD4+ TCR pathway—IL4—psoriasis	0.00028	0.0102	CbGpPWpGaD
Mefenamic acid—PTGS1—Overview of nanoparticle effects—CXCL8—psoriasis	0.000278	0.0102	CbGpPWpGaD
Mefenamic acid—PTGS2—Fluticasone Propionate—Betamethasone—psoriasis	0.000274	0.0346	CbGdCrCtD
Mefenamic acid—PTGS2—Fluticasone Propionate—Dexamethasone—psoriasis	0.000274	0.0346	CbGdCrCtD
Mefenamic acid—AKR1C2—Metabolism of lipids and lipoproteins—CARM1—psoriasis	0.000268	0.00982	CbGpPWpGaD
Mefenamic acid—PTGS2—Fluticasone Propionate—Triamcinolone—psoriasis	0.000267	0.0338	CbGdCrCtD
Mefenamic acid—AKR1C3—Diseases associated with visual transduction—APOE—psoriasis	0.000265	0.0097	CbGpPWpGaD
Mefenamic acid—AKR1C2—Metabolism—CYP2S1—psoriasis	0.000245	0.00895	CbGpPWpGaD
Mefenamic acid—PTGS2—Quercetin and Nf-kB/ AP-1 Induced Cell Apoptosis—JUN—psoriasis	0.000235	0.00861	CbGpPWpGaD
Mefenamic acid—PTGS2—Quercetin and Nf-kB/ AP-1 Induced Cell Apoptosis—NFKB1—psoriasis	0.000227	0.00829	CbGpPWpGaD
Mefenamic acid—PTGS2—Overview of nanoparticle effects—CXCL8—psoriasis	0.000221	0.00807	CbGpPWpGaD
Mefenamic acid—AKR1C1—Metabolism—NDUFA5—psoriasis	0.000211	0.00773	CbGpPWpGaD
Mefenamic acid—PTGS2—Quercetin and Nf-kB/ AP-1 Induced Cell Apoptosis—VEGFA—psoriasis	0.000206	0.00752	CbGpPWpGaD
Mefenamic acid—CYP2C8—Biological oxidations—CYP2S1—psoriasis	0.000199	0.00727	CbGpPWpGaD
Mefenamic acid—AKR1C1—Metabolism of lipids and lipoproteins—CARM1—psoriasis	0.000197	0.00721	CbGpPWpGaD
Mefenamic acid—CYP2C8—Metapathway biotransformation—CYP2S1—psoriasis	0.000196	0.00717	CbGpPWpGaD
Mefenamic acid—PTGS1—Overview of nanoparticle effects—TNF—psoriasis	0.000194	0.00708	CbGpPWpGaD
Mefenamic acid—PTGS2—Signaling mediated by p38-alpha and p38-beta—NOS2—psoriasis	0.00019	0.00694	CbGpPWpGaD
Mefenamic acid—PTGS2—Calcineurin-regulated NFAT-dependent transcription in lymphocytes—IL4—psoriasis	0.000181	0.00662	CbGpPWpGaD
Mefenamic acid—AKR1C1—Metabolism—CYP2S1—psoriasis	0.00018	0.00657	CbGpPWpGaD
Mefenamic acid—PTGS2—S1P1 pathway—VEGFA—psoriasis	0.000179	0.00656	CbGpPWpGaD
Mefenamic acid—Decreased appetite—Mycophenolate mofetil—psoriasis	0.000174	0.000544	CcSEcCtD
Mefenamic acid—Anorexia—Hydrocortisone—psoriasis	0.000174	0.000544	CcSEcCtD
Mefenamic acid—Diarrhoea—Mycophenolic acid—psoriasis	0.000174	0.000543	CcSEcCtD
Mefenamic acid—Stomatitis—Methotrexate—psoriasis	0.000174	0.000542	CcSEcCtD
Mefenamic acid—Conjunctivitis—Methotrexate—psoriasis	0.000173	0.000541	CcSEcCtD
Mefenamic acid—Gastrointestinal disorder—Mycophenolate mofetil—psoriasis	0.000173	0.000541	CcSEcCtD
Mefenamic acid—CYP2C9—Nuclear Receptors in Lipid Metabolism and Toxicity—VDR—psoriasis	0.000173	0.00631	CbGpPWpGaD
Mefenamic acid—Malaise—Dexamethasone—psoriasis	0.000172	0.000539	CcSEcCtD
Mefenamic acid—Malaise—Betamethasone—psoriasis	0.000172	0.000539	CcSEcCtD
Mefenamic acid—Anaphylactic shock—Triamcinolone—psoriasis	0.000172	0.000537	CcSEcCtD
Mefenamic acid—Oedema—Triamcinolone—psoriasis	0.000172	0.000537	CcSEcCtD
Mefenamic acid—Vertigo—Betamethasone—psoriasis	0.000172	0.000537	CcSEcCtD
Mefenamic acid—Vertigo—Dexamethasone—psoriasis	0.000172	0.000537	CcSEcCtD
Mefenamic acid—Syncope—Betamethasone—psoriasis	0.000171	0.000536	CcSEcCtD
Mefenamic acid—Syncope—Dexamethasone—psoriasis	0.000171	0.000536	CcSEcCtD
Mefenamic acid—Constipation—Mycophenolate mofetil—psoriasis	0.000171	0.000536	CcSEcCtD
Mefenamic acid—Arrhythmia—Prednisone—psoriasis	0.000171	0.000534	CcSEcCtD
Mefenamic acid—Infection—Triamcinolone—psoriasis	0.000171	0.000534	CcSEcCtD
Mefenamic acid—Hypotension—Hydrocortisone—psoriasis	0.000171	0.000533	CcSEcCtD
Mefenamic acid—Haematuria—Methotrexate—psoriasis	0.00017	0.00053	CcSEcCtD
Mefenamic acid—Feeling abnormal—Cyclosporine—psoriasis	0.000169	0.000529	CcSEcCtD
Mefenamic acid—PTGS2—Calcium signaling in the CD4+ TCR pathway—IFNG—psoriasis	0.000169	0.00619	CbGpPWpGaD
Mefenamic acid—Shock—Triamcinolone—psoriasis	0.000169	0.000529	CcSEcCtD
Mefenamic acid—Insomnia—Prednisolone—psoriasis	0.000169	0.000528	CcSEcCtD
Mefenamic acid—Alopecia—Prednisone—psoriasis	0.000169	0.000528	CcSEcCtD
Mefenamic acid—Gastrointestinal pain—Cyclosporine—psoriasis	0.000168	0.000525	CcSEcCtD
Mefenamic acid—Loss of consciousness—Betamethasone—psoriasis	0.000168	0.000525	CcSEcCtD
Mefenamic acid—Loss of consciousness—Dexamethasone—psoriasis	0.000168	0.000525	CcSEcCtD
Mefenamic acid—Dizziness—Mycophenolic acid—psoriasis	0.000168	0.000525	CcSEcCtD
Mefenamic acid—Paraesthesia—Prednisolone—psoriasis	0.000168	0.000525	CcSEcCtD
Mefenamic acid—Tachycardia—Triamcinolone—psoriasis	0.000168	0.000524	CcSEcCtD
Mefenamic acid—Mental disorder—Prednisone—psoriasis	0.000168	0.000524	CcSEcCtD
Mefenamic acid—Agranulocytosis—Methotrexate—psoriasis	0.000166	0.000519	CcSEcCtD
Mefenamic acid—AKR1C1—Signaling Pathways—HCAR2—psoriasis	0.000166	0.00608	CbGpPWpGaD
Mefenamic acid—Convulsion—Betamethasone—psoriasis	0.000166	0.000518	CcSEcCtD
Mefenamic acid—Convulsion—Dexamethasone—psoriasis	0.000166	0.000518	CcSEcCtD
Mefenamic acid—Feeling abnormal—Mycophenolate mofetil—psoriasis	0.000165	0.000516	CcSEcCtD
Mefenamic acid—Insomnia—Hydrocortisone—psoriasis	0.000165	0.000516	CcSEcCtD
Mefenamic acid—Hypertension—Dexamethasone—psoriasis	0.000165	0.000516	CcSEcCtD
Mefenamic acid—Hypertension—Betamethasone—psoriasis	0.000165	0.000516	CcSEcCtD
Mefenamic acid—Paraesthesia—Hydrocortisone—psoriasis	0.000164	0.000512	CcSEcCtD
Mefenamic acid—Gastrointestinal pain—Mycophenolate mofetil—psoriasis	0.000164	0.000512	CcSEcCtD
Mefenamic acid—Urticaria—Cyclosporine—psoriasis	0.000163	0.00051	CcSEcCtD
Mefenamic acid—Body temperature increased—Cyclosporine—psoriasis	0.000162	0.000508	CcSEcCtD
Mefenamic acid—Abdominal pain—Cyclosporine—psoriasis	0.000162	0.000508	CcSEcCtD
Mefenamic acid—Anxiety—Dexamethasone—psoriasis	0.000162	0.000507	CcSEcCtD
Mefenamic acid—Anxiety—Betamethasone—psoriasis	0.000162	0.000507	CcSEcCtD
Mefenamic acid—CYP2C9—Biological oxidations—CYP2S1—psoriasis	0.000162	0.00592	CbGpPWpGaD
Mefenamic acid—Vomiting—Mycophenolic acid—psoriasis	0.000161	0.000505	CcSEcCtD
Mefenamic acid—Discomfort—Dexamethasone—psoriasis	0.000161	0.000502	CcSEcCtD
Mefenamic acid—Discomfort—Betamethasone—psoriasis	0.000161	0.000502	CcSEcCtD
Mefenamic acid—Dyspepsia—Hydrocortisone—psoriasis	0.000161	0.000502	CcSEcCtD
Mefenamic acid—Haemoglobin—Methotrexate—psoriasis	0.000161	0.000502	CcSEcCtD
Mefenamic acid—Rash—Mycophenolic acid—psoriasis	0.00016	0.0005	CcSEcCtD
Mefenamic acid—Dermatitis—Mycophenolic acid—psoriasis	0.00016	0.0005	CcSEcCtD
Mefenamic acid—Haemorrhage—Methotrexate—psoriasis	0.00016	0.000499	CcSEcCtD
Mefenamic acid—Hepatitis—Methotrexate—psoriasis	0.00016	0.000499	CcSEcCtD
Mefenamic acid—CYP2C9—Metapathway biotransformation—CYP2S1—psoriasis	0.00016	0.00584	CbGpPWpGaD
Mefenamic acid—Urticaria—Mycophenolate mofetil—psoriasis	0.000159	0.000498	CcSEcCtD
Mefenamic acid—Headache—Mycophenolic acid—psoriasis	0.000159	0.000497	CcSEcCtD
Mefenamic acid—Decreased appetite—Hydrocortisone—psoriasis	0.000159	0.000496	CcSEcCtD
Mefenamic acid—Abdominal pain—Mycophenolate mofetil—psoriasis	0.000158	0.000495	CcSEcCtD
Mefenamic acid—Body temperature increased—Mycophenolate mofetil—psoriasis	0.000158	0.000495	CcSEcCtD
Mefenamic acid—PTGS1—Selenium Micronutrient Network—CAT—psoriasis	0.000158	0.00578	CbGpPWpGaD
Mefenamic acid—Urinary tract disorder—Methotrexate—psoriasis	0.000158	0.000493	CcSEcCtD
Mefenamic acid—Gastrointestinal disorder—Hydrocortisone—psoriasis	0.000158	0.000493	CcSEcCtD
Mefenamic acid—Vision blurred—Prednisone—psoriasis	0.000157	0.00049	CcSEcCtD
Mefenamic acid—Urethral disorder—Methotrexate—psoriasis	0.000157	0.00049	CcSEcCtD
Mefenamic acid—PTGS1—Overview of nanoparticle effects—IL6—psoriasis	0.000156	0.00571	CbGpPWpGaD
Mefenamic acid—Anaphylactic shock—Betamethasone—psoriasis	0.000156	0.000487	CcSEcCtD
Mefenamic acid—Oedema—Betamethasone—psoriasis	0.000156	0.000487	CcSEcCtD
Mefenamic acid—Oedema—Dexamethasone—psoriasis	0.000156	0.000487	CcSEcCtD
Mefenamic acid—Anaphylactic shock—Dexamethasone—psoriasis	0.000156	0.000487	CcSEcCtD
Mefenamic acid—Insomnia—Triamcinolone—psoriasis	0.000155	0.000486	CcSEcCtD
Mefenamic acid—Infection—Betamethasone—psoriasis	0.000155	0.000484	CcSEcCtD
Mefenamic acid—Infection—Dexamethasone—psoriasis	0.000155	0.000484	CcSEcCtD
Mefenamic acid—Ill-defined disorder—Prednisone—psoriasis	0.000154	0.000483	CcSEcCtD
Mefenamic acid—Paraesthesia—Triamcinolone—psoriasis	0.000154	0.000482	CcSEcCtD
Mefenamic acid—Feeling abnormal—Prednisolone—psoriasis	0.000154	0.000481	CcSEcCtD
Mefenamic acid—Anaemia—Prednisone—psoriasis	0.000154	0.000481	CcSEcCtD
Mefenamic acid—PTGS2—Overview of nanoparticle effects—TNF—psoriasis	0.000154	0.00562	CbGpPWpGaD
Mefenamic acid—Shock—Betamethasone—psoriasis	0.000153	0.00048	CcSEcCtD
Mefenamic acid—Shock—Dexamethasone—psoriasis	0.000153	0.00048	CcSEcCtD
Mefenamic acid—Dyspnoea—Triamcinolone—psoriasis	0.000153	0.000479	CcSEcCtD
Mefenamic acid—Thrombocytopenia—Dexamethasone—psoriasis	0.000153	0.000477	CcSEcCtD
Mefenamic acid—Thrombocytopenia—Betamethasone—psoriasis	0.000153	0.000477	CcSEcCtD
Mefenamic acid—Tachycardia—Dexamethasone—psoriasis	0.000152	0.000476	CcSEcCtD
Mefenamic acid—Tachycardia—Betamethasone—psoriasis	0.000152	0.000476	CcSEcCtD
Mefenamic acid—Angioedema—Prednisone—psoriasis	0.000152	0.000475	CcSEcCtD
Mefenamic acid—Dyspepsia—Triamcinolone—psoriasis	0.000151	0.000473	CcSEcCtD
Mefenamic acid—Erythema multiforme—Methotrexate—psoriasis	0.000151	0.000472	CcSEcCtD
Mefenamic acid—Nausea—Mycophenolic acid—psoriasis	0.000151	0.000471	CcSEcCtD
Mefenamic acid—Feeling abnormal—Hydrocortisone—psoriasis	0.00015	0.00047	CcSEcCtD
Mefenamic acid—Malaise—Prednisone—psoriasis	0.00015	0.000469	CcSEcCtD
Mefenamic acid—Vertigo—Prednisone—psoriasis	0.00015	0.000467	CcSEcCtD
Mefenamic acid—Gastrointestinal pain—Hydrocortisone—psoriasis	0.000149	0.000467	CcSEcCtD
Mefenamic acid—Syncope—Prednisone—psoriasis	0.000149	0.000466	CcSEcCtD
Mefenamic acid—Tinnitus—Methotrexate—psoriasis	0.000149	0.000466	CcSEcCtD
Mefenamic acid—Anorexia—Dexamethasone—psoriasis	0.000149	0.000465	CcSEcCtD
Mefenamic acid—Anorexia—Betamethasone—psoriasis	0.000149	0.000465	CcSEcCtD
Mefenamic acid—Urticaria—Prednisolone—psoriasis	0.000149	0.000464	CcSEcCtD
Mefenamic acid—Asthenia—Cyclosporine—psoriasis	0.000147	0.000461	CcSEcCtD
Mefenamic acid—PTGS2—Calcium signaling in the CD4+ TCR pathway—JUN—psoriasis	0.000146	0.00535	CbGpPWpGaD
Mefenamic acid—Loss of consciousness—Prednisone—psoriasis	0.000146	0.000457	CcSEcCtD
Mefenamic acid—Hypotension—Betamethasone—psoriasis	0.000146	0.000456	CcSEcCtD
Mefenamic acid—Hypotension—Dexamethasone—psoriasis	0.000146	0.000456	CcSEcCtD
Mefenamic acid—Pruritus—Cyclosporine—psoriasis	0.000145	0.000454	CcSEcCtD
Mefenamic acid—Urticaria—Hydrocortisone—psoriasis	0.000145	0.000453	CcSEcCtD
Mefenamic acid—Abdominal pain—Hydrocortisone—psoriasis	0.000144	0.000451	CcSEcCtD
Mefenamic acid—Body temperature increased—Hydrocortisone—psoriasis	0.000144	0.000451	CcSEcCtD
Mefenamic acid—Convulsion—Prednisone—psoriasis	0.000144	0.000451	CcSEcCtD
Mefenamic acid—AKR1C1—Signaling Pathways—TAGAP—psoriasis	0.000144	0.00527	CbGpPWpGaD
Mefenamic acid—Asthenia—Mycophenolate mofetil—psoriasis	0.000144	0.000449	CcSEcCtD
Mefenamic acid—Hypertension—Prednisone—psoriasis	0.000144	0.000449	CcSEcCtD
Mefenamic acid—PTGS2—Integrated Pancreatic Cancer Pathway—PTTG1—psoriasis	0.000143	0.00522	CbGpPWpGaD
Mefenamic acid—AKR1C3—Metabolism—NDUFA5—psoriasis	0.000142	0.0052	CbGpPWpGaD
Mefenamic acid—Pruritus—Mycophenolate mofetil—psoriasis	0.000142	0.000443	CcSEcCtD
Mefenamic acid—Feeling abnormal—Triamcinolone—psoriasis	0.000142	0.000443	CcSEcCtD
Mefenamic acid—Anxiety—Prednisone—psoriasis	0.000141	0.000441	CcSEcCtD
Mefenamic acid—Alopecia—Methotrexate—psoriasis	0.000141	0.000441	CcSEcCtD
Mefenamic acid—Insomnia—Dexamethasone—psoriasis	0.000141	0.000441	CcSEcCtD
Mefenamic acid—Insomnia—Betamethasone—psoriasis	0.000141	0.000441	CcSEcCtD
Mefenamic acid—Unspecified disorder of skin and subcutaneous tissue—Prednisone—psoriasis	0.000141	0.00044	CcSEcCtD
Mefenamic acid—Diarrhoea—Cyclosporine—psoriasis	0.000141	0.000439	CcSEcCtD
Mefenamic acid—Paraesthesia—Dexamethasone—psoriasis	0.00014	0.000438	CcSEcCtD
Mefenamic acid—Paraesthesia—Betamethasone—psoriasis	0.00014	0.000438	CcSEcCtD
Mefenamic acid—Discomfort—Prednisone—psoriasis	0.00014	0.000438	CcSEcCtD
Mefenamic acid—Mental disorder—Methotrexate—psoriasis	0.00014	0.000438	CcSEcCtD
Mefenamic acid—Dyspepsia—Betamethasone—psoriasis	0.000137	0.000429	CcSEcCtD
Mefenamic acid—Dyspepsia—Dexamethasone—psoriasis	0.000137	0.000429	CcSEcCtD
Mefenamic acid—Diarrhoea—Mycophenolate mofetil—psoriasis	0.000137	0.000429	CcSEcCtD
Mefenamic acid—Urticaria—Triamcinolone—psoriasis	0.000137	0.000427	CcSEcCtD
Mefenamic acid—Body temperature increased—Triamcinolone—psoriasis	0.000136	0.000425	CcSEcCtD
Mefenamic acid—Dizziness—Cyclosporine—psoriasis	0.000136	0.000425	CcSEcCtD
Mefenamic acid—Anaphylactic shock—Prednisone—psoriasis	0.000136	0.000425	CcSEcCtD
Mefenamic acid—Oedema—Prednisone—psoriasis	0.000136	0.000425	CcSEcCtD
Mefenamic acid—Decreased appetite—Betamethasone—psoriasis	0.000136	0.000424	CcSEcCtD
Mefenamic acid—Decreased appetite—Dexamethasone—psoriasis	0.000136	0.000424	CcSEcCtD
Mefenamic acid—Infection—Prednisone—psoriasis	0.000135	0.000422	CcSEcCtD
Mefenamic acid—Gastrointestinal disorder—Betamethasone—psoriasis	0.000135	0.000421	CcSEcCtD
Mefenamic acid—Gastrointestinal disorder—Dexamethasone—psoriasis	0.000135	0.000421	CcSEcCtD
Mefenamic acid—Shock—Prednisone—psoriasis	0.000134	0.000418	CcSEcCtD
Mefenamic acid—PTGS2—Calcineurin-regulated NFAT-dependent transcription in lymphocytes—PPARG—psoriasis	0.000133	0.00488	CbGpPWpGaD
Mefenamic acid—Tachycardia—Prednisone—psoriasis	0.000133	0.000414	CcSEcCtD
Mefenamic acid—AKR1C3—Metabolism of lipids and lipoproteins—CARM1—psoriasis	0.000133	0.00485	CbGpPWpGaD
Mefenamic acid—Dizziness—Mycophenolate mofetil—psoriasis	0.000133	0.000414	CcSEcCtD
Mefenamic acid—Skin disorder—Prednisone—psoriasis	0.000132	0.000412	CcSEcCtD
Mefenamic acid—Vision blurred—Methotrexate—psoriasis	0.000131	0.00041	CcSEcCtD
Mefenamic acid—Asthenia—Hydrocortisone—psoriasis	0.000131	0.000409	CcSEcCtD
Mefenamic acid—Vomiting—Cyclosporine—psoriasis	0.000131	0.000408	CcSEcCtD
Mefenamic acid—Rash—Cyclosporine—psoriasis	0.00013	0.000405	CcSEcCtD
Mefenamic acid—Anorexia—Prednisone—psoriasis	0.000129	0.000405	CcSEcCtD
Mefenamic acid—Dermatitis—Cyclosporine—psoriasis	0.000129	0.000404	CcSEcCtD
Mefenamic acid—Pruritus—Hydrocortisone—psoriasis	0.000129	0.000404	CcSEcCtD
Mefenamic acid—Ill-defined disorder—Methotrexate—psoriasis	0.000129	0.000403	CcSEcCtD
Mefenamic acid—Headache—Cyclosporine—psoriasis	0.000129	0.000402	CcSEcCtD
Mefenamic acid—Anaemia—Methotrexate—psoriasis	0.000129	0.000402	CcSEcCtD
Mefenamic acid—Feeling abnormal—Dexamethasone—psoriasis	0.000129	0.000402	CcSEcCtD
Mefenamic acid—Feeling abnormal—Betamethasone—psoriasis	0.000129	0.000402	CcSEcCtD
Mefenamic acid—AKR1C2—Metabolism of lipids and lipoproteins—APOE—psoriasis	0.000128	0.00469	CbGpPWpGaD
Mefenamic acid—Gastrointestinal pain—Betamethasone—psoriasis	0.000128	0.000399	CcSEcCtD
Mefenamic acid—Gastrointestinal pain—Dexamethasone—psoriasis	0.000128	0.000399	CcSEcCtD
Mefenamic acid—Vomiting—Mycophenolate mofetil—psoriasis	0.000127	0.000398	CcSEcCtD
Mefenamic acid—Rash—Mycophenolate mofetil—psoriasis	0.000126	0.000395	CcSEcCtD
Mefenamic acid—Dermatitis—Mycophenolate mofetil—psoriasis	0.000126	0.000395	CcSEcCtD
Mefenamic acid—PTGS2—Signaling mediated by p38-alpha and p38-beta—JUN—psoriasis	0.000126	0.0046	CbGpPWpGaD
Mefenamic acid—Headache—Mycophenolate mofetil—psoriasis	0.000126	0.000392	CcSEcCtD
Mefenamic acid—Malaise—Methotrexate—psoriasis	0.000125	0.000392	CcSEcCtD
Mefenamic acid—PTGS1—Selenium Micronutrient Network—CRP—psoriasis	0.000125	0.00459	CbGpPWpGaD
Mefenamic acid—PTGS2—Selenium Micronutrient Network—CAT—psoriasis	0.000125	0.00459	CbGpPWpGaD
Mefenamic acid—Vertigo—Methotrexate—psoriasis	0.000125	0.000391	CcSEcCtD
Mefenamic acid—Diarrhoea—Hydrocortisone—psoriasis	0.000125	0.00039	CcSEcCtD
Mefenamic acid—Leukopenia—Methotrexate—psoriasis	0.000125	0.000389	CcSEcCtD
Mefenamic acid—PTGS2—Overview of nanoparticle effects—IL6—psoriasis	0.000124	0.00454	CbGpPWpGaD
Mefenamic acid—Urticaria—Dexamethasone—psoriasis	0.000124	0.000387	CcSEcCtD
Mefenamic acid—Urticaria—Betamethasone—psoriasis	0.000124	0.000387	CcSEcCtD
Mefenamic acid—Dizziness—Prednisolone—psoriasis	0.000124	0.000386	CcSEcCtD
Mefenamic acid—Asthenia—Triamcinolone—psoriasis	0.000123	0.000385	CcSEcCtD
Mefenamic acid—Abdominal pain—Betamethasone—psoriasis	0.000123	0.000385	CcSEcCtD
Mefenamic acid—Body temperature increased—Dexamethasone—psoriasis	0.000123	0.000385	CcSEcCtD
Mefenamic acid—Body temperature increased—Betamethasone—psoriasis	0.000123	0.000385	CcSEcCtD
Mefenamic acid—Abdominal pain—Dexamethasone—psoriasis	0.000123	0.000385	CcSEcCtD
Mefenamic acid—Insomnia—Prednisone—psoriasis	0.000123	0.000384	CcSEcCtD
Mefenamic acid—Nausea—Cyclosporine—psoriasis	0.000122	0.000381	CcSEcCtD
Mefenamic acid—Paraesthesia—Prednisone—psoriasis	0.000122	0.000381	CcSEcCtD
Mefenamic acid—Pruritus—Triamcinolone—psoriasis	0.000122	0.00038	CcSEcCtD
Mefenamic acid—AKR1C3—Metabolism—CYP2S1—psoriasis	0.000121	0.00442	CbGpPWpGaD
Mefenamic acid—Dizziness—Hydrocortisone—psoriasis	0.000121	0.000377	CcSEcCtD
Mefenamic acid—Convulsion—Methotrexate—psoriasis	0.000121	0.000377	CcSEcCtD
Mefenamic acid—CYP2C9—Nuclear Receptors in Lipid Metabolism and Toxicity—PPARG—psoriasis	0.00012	0.0044	CbGpPWpGaD
Mefenamic acid—Dyspepsia—Prednisone—psoriasis	0.00012	0.000374	CcSEcCtD
Mefenamic acid—AKR1C2—Metabolism—CARM1—psoriasis	0.00012	0.00437	CbGpPWpGaD
Mefenamic acid—Nausea—Mycophenolate mofetil—psoriasis	0.000119	0.000372	CcSEcCtD
Mefenamic acid—Decreased appetite—Prednisone—psoriasis	0.000118	0.000369	CcSEcCtD
Mefenamic acid—Rash—Prednisolone—psoriasis	0.000118	0.000368	CcSEcCtD
Mefenamic acid—Dermatitis—Prednisolone—psoriasis	0.000118	0.000368	CcSEcCtD
Mefenamic acid—Unspecified disorder of skin and subcutaneous tissue—Methotrexate—psoriasis	0.000118	0.000368	CcSEcCtD
Mefenamic acid—Headache—Prednisolone—psoriasis	0.000117	0.000366	CcSEcCtD
Mefenamic acid—Discomfort—Methotrexate—psoriasis	0.000117	0.000366	CcSEcCtD
Mefenamic acid—Constipation—Prednisone—psoriasis	0.000116	0.000363	CcSEcCtD
Mefenamic acid—Vomiting—Hydrocortisone—psoriasis	0.000116	0.000363	CcSEcCtD
Mefenamic acid—PTGS1—Selenium Micronutrient Network—ICAM1—psoriasis	0.000115	0.00422	CbGpPWpGaD
Mefenamic acid—Rash—Hydrocortisone—psoriasis	0.000115	0.00036	CcSEcCtD
Mefenamic acid—Dermatitis—Hydrocortisone—psoriasis	0.000115	0.000359	CcSEcCtD
Mefenamic acid—Confusional state—Methotrexate—psoriasis	0.000114	0.000358	CcSEcCtD
Mefenamic acid—Headache—Hydrocortisone—psoriasis	0.000114	0.000357	CcSEcCtD
Mefenamic acid—Dizziness—Triamcinolone—psoriasis	0.000114	0.000355	CcSEcCtD
Mefenamic acid—Anaphylactic shock—Methotrexate—psoriasis	0.000114	0.000355	CcSEcCtD
Mefenamic acid—Infection—Methotrexate—psoriasis	0.000113	0.000352	CcSEcCtD
Mefenamic acid—Feeling abnormal—Prednisone—psoriasis	0.000112	0.00035	CcSEcCtD
Mefenamic acid—Asthenia—Dexamethasone—psoriasis	0.000112	0.00035	CcSEcCtD
Mefenamic acid—Asthenia—Betamethasone—psoriasis	0.000112	0.00035	CcSEcCtD
Mefenamic acid—AKR1C3—Signaling Pathways—HCAR2—psoriasis	0.000112	0.00409	CbGpPWpGaD
Mefenamic acid—AKR1C2—Metabolism of lipids and lipoproteins—PPARG—psoriasis	0.000112	0.00409	CbGpPWpGaD
Mefenamic acid—Thrombocytopenia—Methotrexate—psoriasis	0.000111	0.000347	CcSEcCtD
Mefenamic acid—Gastrointestinal pain—Prednisone—psoriasis	0.000111	0.000347	CcSEcCtD
Mefenamic acid—Nausea—Prednisolone—psoriasis	0.000111	0.000347	CcSEcCtD
Mefenamic acid—Pruritus—Dexamethasone—psoriasis	0.00011	0.000345	CcSEcCtD
Mefenamic acid—Pruritus—Betamethasone—psoriasis	0.00011	0.000345	CcSEcCtD
Mefenamic acid—Skin disorder—Methotrexate—psoriasis	0.00011	0.000345	CcSEcCtD
Mefenamic acid—PTGS2—Calcineurin-regulated NFAT-dependent transcription in lymphocytes—IFNG—psoriasis	0.000109	0.004	CbGpPWpGaD
Mefenamic acid—Vomiting—Triamcinolone—psoriasis	0.000109	0.000342	CcSEcCtD
Mefenamic acid—Nausea—Hydrocortisone—psoriasis	0.000108	0.000339	CcSEcCtD
Mefenamic acid—Rash—Triamcinolone—psoriasis	0.000108	0.000339	CcSEcCtD
Mefenamic acid—Dermatitis—Triamcinolone—psoriasis	0.000108	0.000338	CcSEcCtD
Mefenamic acid—Anorexia—Methotrexate—psoriasis	0.000108	0.000338	CcSEcCtD
Mefenamic acid—Urticaria—Prednisone—psoriasis	0.000108	0.000337	CcSEcCtD
Mefenamic acid—Headache—Triamcinolone—psoriasis	0.000108	0.000337	CcSEcCtD
Mefenamic acid—Abdominal pain—Prednisone—psoriasis	0.000107	0.000336	CcSEcCtD
Mefenamic acid—Body temperature increased—Prednisone—psoriasis	0.000107	0.000336	CcSEcCtD
Mefenamic acid—Diarrhoea—Dexamethasone—psoriasis	0.000107	0.000334	CcSEcCtD
Mefenamic acid—Diarrhoea—Betamethasone—psoriasis	0.000107	0.000334	CcSEcCtD
Mefenamic acid—Hypotension—Methotrexate—psoriasis	0.000106	0.000332	CcSEcCtD
Mefenamic acid—Dizziness—Dexamethasone—psoriasis	0.000103	0.000322	CcSEcCtD
Mefenamic acid—Dizziness—Betamethasone—psoriasis	0.000103	0.000322	CcSEcCtD
Mefenamic acid—Insomnia—Methotrexate—psoriasis	0.000103	0.000321	CcSEcCtD
Mefenamic acid—Nausea—Triamcinolone—psoriasis	0.000102	0.000319	CcSEcCtD
Mefenamic acid—Paraesthesia—Methotrexate—psoriasis	0.000102	0.000319	CcSEcCtD
Mefenamic acid—PTGS2—Calcineurin-regulated NFAT-dependent transcription in lymphocytes—CXCL8—psoriasis	0.000102	0.00372	CbGpPWpGaD
Mefenamic acid—Dyspnoea—Methotrexate—psoriasis	0.000101	0.000316	CcSEcCtD
Mefenamic acid—Somnolence—Methotrexate—psoriasis	0.000101	0.000315	CcSEcCtD
Mefenamic acid—Dyspepsia—Methotrexate—psoriasis	9.99e-05	0.000312	CcSEcCtD
Mefenamic acid—PTGS2—Selenium Micronutrient Network—CRP—psoriasis	9.96e-05	0.00364	CbGpPWpGaD
Mefenamic acid—Vomiting—Betamethasone—psoriasis	9.92e-05	0.00031	CcSEcCtD
Mefenamic acid—Vomiting—Dexamethasone—psoriasis	9.92e-05	0.00031	CcSEcCtD
Mefenamic acid—Decreased appetite—Methotrexate—psoriasis	9.87e-05	0.000308	CcSEcCtD
Mefenamic acid—Rash—Dexamethasone—psoriasis	9.84e-05	0.000307	CcSEcCtD
Mefenamic acid—Rash—Betamethasone—psoriasis	9.84e-05	0.000307	CcSEcCtD
Mefenamic acid—Dermatitis—Betamethasone—psoriasis	9.83e-05	0.000307	CcSEcCtD
Mefenamic acid—Dermatitis—Dexamethasone—psoriasis	9.83e-05	0.000307	CcSEcCtD
Mefenamic acid—Gastrointestinal disorder—Methotrexate—psoriasis	9.8e-05	0.000306	CcSEcCtD
Mefenamic acid—Headache—Betamethasone—psoriasis	9.77e-05	0.000305	CcSEcCtD
Mefenamic acid—Headache—Dexamethasone—psoriasis	9.77e-05	0.000305	CcSEcCtD
Mefenamic acid—Asthenia—Prednisone—psoriasis	9.75e-05	0.000305	CcSEcCtD
Mefenamic acid—PTGS2—Aryl Hydrocarbon Receptor—NFKB1—psoriasis	9.74e-05	0.00356	CbGpPWpGaD
Mefenamic acid—AKR1C3—Signaling Pathways—TAGAP—psoriasis	9.69e-05	0.00354	CbGpPWpGaD
Mefenamic acid—Pruritus—Prednisone—psoriasis	9.61e-05	0.0003	CcSEcCtD
Mefenamic acid—PTGS2—Calcineurin-regulated NFAT-dependent transcription in lymphocytes—JUN—psoriasis	9.46e-05	0.00346	CbGpPWpGaD
Mefenamic acid—AKR1C1—Metabolism of lipids and lipoproteins—APOE—psoriasis	9.41e-05	0.00344	CbGpPWpGaD
Mefenamic acid—Feeling abnormal—Methotrexate—psoriasis	9.36e-05	0.000292	CcSEcCtD
Mefenamic acid—Diarrhoea—Prednisone—psoriasis	9.29e-05	0.00029	CcSEcCtD
Mefenamic acid—Gastrointestinal pain—Methotrexate—psoriasis	9.28e-05	0.00029	CcSEcCtD
Mefenamic acid—Nausea—Betamethasone—psoriasis	9.27e-05	0.00029	CcSEcCtD
Mefenamic acid—Nausea—Dexamethasone—psoriasis	9.27e-05	0.00029	CcSEcCtD
Mefenamic acid—PTGS2—Selenium Micronutrient Network—ICAM1—psoriasis	9.15e-05	0.00335	CbGpPWpGaD
Mefenamic acid—PTGS2—Spinal Cord Injury—IL4—psoriasis	9.11e-05	0.00333	CbGpPWpGaD
Mefenamic acid—Urticaria—Methotrexate—psoriasis	9.02e-05	0.000282	CcSEcCtD
Mefenamic acid—Dizziness—Prednisone—psoriasis	8.98e-05	0.000281	CcSEcCtD
Mefenamic acid—Abdominal pain—Methotrexate—psoriasis	8.97e-05	0.00028	CcSEcCtD
Mefenamic acid—Body temperature increased—Methotrexate—psoriasis	8.97e-05	0.00028	CcSEcCtD
Mefenamic acid—PTGS2—Aryl Hydrocarbon Receptor—VEGFA—psoriasis	8.84e-05	0.00323	CbGpPWpGaD
Mefenamic acid—AKR1C1—Metabolism—CARM1—psoriasis	8.77e-05	0.00321	CbGpPWpGaD
Mefenamic acid—PTGS1—Selenium Micronutrient Network—IFNG—psoriasis	8.77e-05	0.00321	CbGpPWpGaD
Mefenamic acid—Vomiting—Prednisone—psoriasis	8.64e-05	0.00027	CcSEcCtD
Mefenamic acid—AKR1C1—Signaling Pathways—CCL20—psoriasis	8.63e-05	0.00316	CbGpPWpGaD
Mefenamic acid—Rash—Prednisone—psoriasis	8.57e-05	0.000268	CcSEcCtD
Mefenamic acid—Dermatitis—Prednisone—psoriasis	8.56e-05	0.000267	CcSEcCtD
Mefenamic acid—Headache—Prednisone—psoriasis	8.51e-05	0.000266	CcSEcCtD
Mefenamic acid—PTGS2—Signaling mediated by p38-alpha and p38-beta—TP53—psoriasis	8.31e-05	0.00304	CbGpPWpGaD
Mefenamic acid—AKR1C1—Metabolism of lipids and lipoproteins—PPARG—psoriasis	8.2e-05	0.003	CbGpPWpGaD
Mefenamic acid—Asthenia—Methotrexate—psoriasis	8.15e-05	0.000255	CcSEcCtD
Mefenamic acid—Nausea—Prednisone—psoriasis	8.07e-05	0.000252	CcSEcCtD
Mefenamic acid—Pruritus—Methotrexate—psoriasis	8.03e-05	0.000251	CcSEcCtD
Mefenamic acid—Diarrhoea—Methotrexate—psoriasis	7.77e-05	0.000243	CcSEcCtD
Mefenamic acid—PTGS2—Spinal Cord Injury—LEP—psoriasis	7.71e-05	0.00282	CbGpPWpGaD
Mefenamic acid—PTGS2—Aryl Hydrocarbon Receptor—TNF—psoriasis	7.57e-05	0.00277	CbGpPWpGaD
Mefenamic acid—Dizziness—Methotrexate—psoriasis	7.51e-05	0.000235	CcSEcCtD
Mefenamic acid—AKR1C2—Metabolism—CAT—psoriasis	7.35e-05	0.00269	CbGpPWpGaD
Mefenamic acid—PTGS1—Selenium Micronutrient Network—NFKB1—psoriasis	7.3e-05	0.00267	CbGpPWpGaD
Mefenamic acid—PTGS2—Spinal Cord Injury—ICAM1—psoriasis	7.24e-05	0.00265	CbGpPWpGaD
Mefenamic acid—Vomiting—Methotrexate—psoriasis	7.22e-05	0.000226	CcSEcCtD
Mefenamic acid—PTGS2—Spinal Cord Injury—NOS2—psoriasis	7.18e-05	0.00263	CbGpPWpGaD
Mefenamic acid—Rash—Methotrexate—psoriasis	7.16e-05	0.000224	CcSEcCtD
Mefenamic acid—Dermatitis—Methotrexate—psoriasis	7.15e-05	0.000224	CcSEcCtD
Mefenamic acid—Headache—Methotrexate—psoriasis	7.11e-05	0.000222	CcSEcCtD
Mefenamic acid—PTGS2—Calcineurin-regulated NFAT-dependent transcription in lymphocytes—TNF—psoriasis	7.09e-05	0.00259	CbGpPWpGaD
Mefenamic acid—PTGS2—C-MYB transcription factor network—CD4—psoriasis	6.98e-05	0.00255	CbGpPWpGaD
Mefenamic acid—PTGS2—Selenium Micronutrient Network—IFNG—psoriasis	6.96e-05	0.00255	CbGpPWpGaD
Mefenamic acid—Nausea—Methotrexate—psoriasis	6.74e-05	0.000211	CcSEcCtD
Mefenamic acid—AKR1C3—Metabolism of lipids and lipoproteins—APOE—psoriasis	6.33e-05	0.00232	CbGpPWpGaD
Mefenamic acid—PTGS1—Metabolism—NDUFA5—psoriasis	6.19e-05	0.00226	CbGpPWpGaD
Mefenamic acid—AKR1C3—Metabolism—CARM1—psoriasis	5.9e-05	0.00216	CbGpPWpGaD
Mefenamic acid—PTGS2—Integrated Pancreatic Cancer Pathway—PCNA—psoriasis	5.81e-05	0.00213	CbGpPWpGaD
Mefenamic acid—AKR1C3—Signaling Pathways—CCL20—psoriasis	5.81e-05	0.00212	CbGpPWpGaD
Mefenamic acid—PTGS2—Selenium Micronutrient Network—NFKB1—psoriasis	5.79e-05	0.00212	CbGpPWpGaD
Mefenamic acid—PTGS1—Metabolism of lipids and lipoproteins—CARM1—psoriasis	5.77e-05	0.00211	CbGpPWpGaD
Mefenamic acid—AKR1C2—Metabolism—APOE—psoriasis	5.71e-05	0.00209	CbGpPWpGaD
Mefenamic acid—PTGS1—Selenium Micronutrient Network—TNF—psoriasis	5.68e-05	0.00208	CbGpPWpGaD
Mefenamic acid—AKR1C3—Metabolism of lipids and lipoproteins—PPARG—psoriasis	5.52e-05	0.00202	CbGpPWpGaD
Mefenamic acid—PTGS2—Spinal Cord Injury—IFNG—psoriasis	5.51e-05	0.00201	CbGpPWpGaD
Mefenamic acid—AKR1C1—Metabolism—CAT—psoriasis	5.4e-05	0.00197	CbGpPWpGaD
Mefenamic acid—AKR1C1—Disease—HLA-A—psoriasis	5.36e-05	0.00196	CbGpPWpGaD
Mefenamic acid—PTGS1—Metabolism—CYP2S1—psoriasis	5.26e-05	0.00192	CbGpPWpGaD
Mefenamic acid—PTGS2—Spinal Cord Injury—CXCL8—psoriasis	5.12e-05	0.00187	CbGpPWpGaD
Mefenamic acid—AKR1C1—Disease—APOE—psoriasis	5.01e-05	0.00183	CbGpPWpGaD
Mefenamic acid—AKR1C2—Metabolism—PPARG—psoriasis	4.98e-05	0.00182	CbGpPWpGaD
Mefenamic acid—PTGS2—Metabolism—NDUFA5—psoriasis	4.91e-05	0.0018	CbGpPWpGaD
Mefenamic acid—PTGS2—Integrated Pancreatic Cancer Pathway—NFKBIA—psoriasis	4.88e-05	0.00179	CbGpPWpGaD
Mefenamic acid—AKR1C1—Signaling Pathways—SOCS1—psoriasis	4.75e-05	0.00174	CbGpPWpGaD
Mefenamic acid—AKR1C1—Disease—NOS2—psoriasis	4.67e-05	0.00171	CbGpPWpGaD
Mefenamic acid—PTGS1—Selenium Micronutrient Network—IL6—psoriasis	4.58e-05	0.00168	CbGpPWpGaD
Mefenamic acid—PTGS2—Metabolism of lipids and lipoproteins—CARM1—psoriasis	4.58e-05	0.00168	CbGpPWpGaD
Mefenamic acid—PTGS2—Selenium Micronutrient Network—TNF—psoriasis	4.51e-05	0.00165	CbGpPWpGaD
Mefenamic acid—AKR1C1—Metabolism—APOE—psoriasis	4.19e-05	0.00153	CbGpPWpGaD
Mefenamic acid—PTGS2—Metabolism—CYP2S1—psoriasis	4.18e-05	0.00153	CbGpPWpGaD
Mefenamic acid—CYP2C8—Metabolism—NDUFA5—psoriasis	4e-05	0.00146	CbGpPWpGaD
Mefenamic acid—AKR1C1—Disease—TYK2—psoriasis	3.82e-05	0.0014	CbGpPWpGaD
Mefenamic acid—CYP2C8—Metabolism of lipids and lipoproteins—CARM1—psoriasis	3.73e-05	0.00136	CbGpPWpGaD
Mefenamic acid—AKR1C1—Metabolism—PPARG—psoriasis	3.65e-05	0.00134	CbGpPWpGaD
Mefenamic acid—PTGS2—Selenium Micronutrient Network—IL6—psoriasis	3.64e-05	0.00133	CbGpPWpGaD
Mefenamic acid—AKR1C3—Metabolism—CAT—psoriasis	3.63e-05	0.00133	CbGpPWpGaD
Mefenamic acid—AKR1C3—Disease—HLA-A—psoriasis	3.61e-05	0.00132	CbGpPWpGaD
Mefenamic acid—PTGS2—Spinal Cord Injury—TNF—psoriasis	3.56e-05	0.0013	CbGpPWpGaD
Mefenamic acid—AKR1C1—Signaling Pathways—LEP—psoriasis	3.51e-05	0.00128	CbGpPWpGaD
Mefenamic acid—AKR1C1—Signaling Pathways—APOE—psoriasis	3.51e-05	0.00128	CbGpPWpGaD
Mefenamic acid—AKR1C1—Disease—CD4—psoriasis	3.46e-05	0.00126	CbGpPWpGaD
Mefenamic acid—CYP2C8—Metabolism—CYP2S1—psoriasis	3.4e-05	0.00124	CbGpPWpGaD
Mefenamic acid—AKR1C3—Disease—APOE—psoriasis	3.37e-05	0.00123	CbGpPWpGaD
Mefenamic acid—AKR1C1—Signaling Pathways—NFKBIA—psoriasis	3.27e-05	0.00119	CbGpPWpGaD
Mefenamic acid—CYP2C9—Metabolism—NDUFA5—psoriasis	3.25e-05	0.00119	CbGpPWpGaD
Mefenamic acid—PTGS2—Integrated Pancreatic Cancer Pathway—JUN—psoriasis	3.24e-05	0.00118	CbGpPWpGaD
Mefenamic acid—AKR1C3—Signaling Pathways—SOCS1—psoriasis	3.2e-05	0.00117	CbGpPWpGaD
Mefenamic acid—PTGS2—Spinal Cord Injury—TP53—psoriasis	3.14e-05	0.00115	CbGpPWpGaD
Mefenamic acid—AKR1C3—Disease—NOS2—psoriasis	3.14e-05	0.00115	CbGpPWpGaD
Mefenamic acid—PTGS2—Integrated Pancreatic Cancer Pathway—NFKB1—psoriasis	3.12e-05	0.00114	CbGpPWpGaD
Mefenamic acid—CYP2C9—Metabolism of lipids and lipoproteins—CARM1—psoriasis	3.03e-05	0.00111	CbGpPWpGaD
Mefenamic acid—PTGS2—Spinal Cord Injury—IL6—psoriasis	2.88e-05	0.00105	CbGpPWpGaD
Mefenamic acid—PTGS2—Integrated Pancreatic Cancer Pathway—VEGFA—psoriasis	2.83e-05	0.00103	CbGpPWpGaD
Mefenamic acid—AKR1C3—Metabolism—APOE—psoriasis	2.82e-05	0.00103	CbGpPWpGaD
Mefenamic acid—CYP2C9—Metabolism—CYP2S1—psoriasis	2.77e-05	0.00101	CbGpPWpGaD
Mefenamic acid—PTGS1—Metabolism of lipids and lipoproteins—APOE—psoriasis	2.76e-05	0.00101	CbGpPWpGaD
Mefenamic acid—AKR1C1—Signaling Pathways—TYK2—psoriasis	2.68e-05	0.000979	CbGpPWpGaD
Mefenamic acid—AKR1C1—Disease—STAT3—psoriasis	2.68e-05	0.000979	CbGpPWpGaD
Mefenamic acid—AKR1C3—Disease—TYK2—psoriasis	2.57e-05	0.000941	CbGpPWpGaD
Mefenamic acid—PTGS1—Metabolism—CARM1—psoriasis	2.57e-05	0.00094	CbGpPWpGaD
Mefenamic acid—AKR1C3—Metabolism—PPARG—psoriasis	2.46e-05	0.000899	CbGpPWpGaD
Mefenamic acid—PTGS2—Integrated Pancreatic Cancer Pathway—TNF—psoriasis	2.42e-05	0.000887	CbGpPWpGaD
Mefenamic acid—PTGS1—Metabolism of lipids and lipoproteins—PPARG—psoriasis	2.4e-05	0.000879	CbGpPWpGaD
Mefenamic acid—AKR1C3—Signaling Pathways—LEP—psoriasis	2.36e-05	0.000863	CbGpPWpGaD
Mefenamic acid—AKR1C3—Signaling Pathways—APOE—psoriasis	2.36e-05	0.000863	CbGpPWpGaD
Mefenamic acid—AKR1C1—Signaling Pathways—CXCL8—psoriasis	2.33e-05	0.000852	CbGpPWpGaD
Mefenamic acid—AKR1C3—Disease—CD4—psoriasis	2.33e-05	0.000851	CbGpPWpGaD
Mefenamic acid—AKR1C3—Signaling Pathways—NFKBIA—psoriasis	2.2e-05	0.000804	CbGpPWpGaD
Mefenamic acid—PTGS2—Metabolism of lipids and lipoproteins—APOE—psoriasis	2.19e-05	0.000801	CbGpPWpGaD
Mefenamic acid—AKR1C1—Signaling Pathways—JUN—psoriasis	2.17e-05	0.000792	CbGpPWpGaD
Mefenamic acid—PTGS2—Integrated Pancreatic Cancer Pathway—TP53—psoriasis	2.14e-05	0.000782	CbGpPWpGaD
Mefenamic acid—AKR1C1—Signaling Pathways—NFKB1—psoriasis	2.08e-05	0.000763	CbGpPWpGaD
Mefenamic acid—PTGS2—Metabolism—CARM1—psoriasis	2.04e-05	0.000746	CbGpPWpGaD
Mefenamic acid—PTGS2—Metabolism of lipids and lipoproteins—PPARG—psoriasis	1.91e-05	0.000697	CbGpPWpGaD
Mefenamic acid—AKR1C1—Signaling Pathways—VEGFA—psoriasis	1.89e-05	0.000692	CbGpPWpGaD
Mefenamic acid—AKR1C1—Signaling Pathways—STAT3—psoriasis	1.87e-05	0.000685	CbGpPWpGaD
Mefenamic acid—AKR1C1—Disease—IL6—psoriasis	1.87e-05	0.000684	CbGpPWpGaD
Mefenamic acid—AKR1C3—Signaling Pathways—TYK2—psoriasis	1.8e-05	0.000659	CbGpPWpGaD
Mefenamic acid—AKR1C3—Disease—STAT3—psoriasis	1.8e-05	0.000659	CbGpPWpGaD
Mefenamic acid—CYP2C8—Metabolism of lipids and lipoproteins—APOE—psoriasis	1.78e-05	0.000652	CbGpPWpGaD
Mefenamic acid—CYP2C8—Metabolism—CARM1—psoriasis	1.66e-05	0.000607	CbGpPWpGaD
Mefenamic acid—PTGS1—Metabolism—CAT—psoriasis	1.58e-05	0.000578	CbGpPWpGaD
Mefenamic acid—AKR1C3—Signaling Pathways—CXCL8—psoriasis	1.57e-05	0.000573	CbGpPWpGaD
Mefenamic acid—CYP2C8—Metabolism of lipids and lipoproteins—PPARG—psoriasis	1.55e-05	0.000567	CbGpPWpGaD
Mefenamic acid—AKR1C3—Signaling Pathways—JUN—psoriasis	1.46e-05	0.000533	CbGpPWpGaD
Mefenamic acid—CYP2C9—Metabolism of lipids and lipoproteins—APOE—psoriasis	1.45e-05	0.00053	CbGpPWpGaD
Mefenamic acid—AKR1C1—Signaling Pathways—TP53—psoriasis	1.43e-05	0.000523	CbGpPWpGaD
Mefenamic acid—AKR1C3—Signaling Pathways—NFKB1—psoriasis	1.4e-05	0.000513	CbGpPWpGaD
Mefenamic acid—CYP2C9—Metabolism—CARM1—psoriasis	1.35e-05	0.000494	CbGpPWpGaD
Mefenamic acid—AKR1C1—Signaling Pathways—IL6—psoriasis	1.31e-05	0.000479	CbGpPWpGaD
Mefenamic acid—AKR1C3—Signaling Pathways—VEGFA—psoriasis	1.27e-05	0.000466	CbGpPWpGaD
Mefenamic acid—CYP2C9—Metabolism of lipids and lipoproteins—PPARG—psoriasis	1.26e-05	0.000462	CbGpPWpGaD
Mefenamic acid—AKR1C3—Signaling Pathways—STAT3—psoriasis	1.26e-05	0.000461	CbGpPWpGaD
Mefenamic acid—AKR1C3—Disease—IL6—psoriasis	1.26e-05	0.00046	CbGpPWpGaD
Mefenamic acid—PTGS2—Metabolism—CAT—psoriasis	1.25e-05	0.000459	CbGpPWpGaD
Mefenamic acid—PTGS2—Disease—HLA-A—psoriasis	1.25e-05	0.000456	CbGpPWpGaD
Mefenamic acid—PTGS1—Metabolism—APOE—psoriasis	1.23e-05	0.000449	CbGpPWpGaD
Mefenamic acid—PTGS2—Disease—APOE—psoriasis	1.16e-05	0.000426	CbGpPWpGaD
Mefenamic acid—PTGS2—Disease—NOS2—psoriasis	1.08e-05	0.000397	CbGpPWpGaD
Mefenamic acid—PTGS1—Metabolism—PPARG—psoriasis	1.07e-05	0.000391	CbGpPWpGaD
Mefenamic acid—CYP2C8—Metabolism—CAT—psoriasis	1.02e-05	0.000373	CbGpPWpGaD
Mefenamic acid—PTGS2—Metabolism—APOE—psoriasis	9.75e-06	0.000357	CbGpPWpGaD
Mefenamic acid—AKR1C3—Signaling Pathways—TP53—psoriasis	9.62e-06	0.000352	CbGpPWpGaD
Mefenamic acid—PTGS2—Disease—TYK2—psoriasis	8.88e-06	0.000325	CbGpPWpGaD
Mefenamic acid—AKR1C3—Signaling Pathways—IL6—psoriasis	8.81e-06	0.000322	CbGpPWpGaD
Mefenamic acid—PTGS2—Metabolism—PPARG—psoriasis	8.49e-06	0.000311	CbGpPWpGaD
Mefenamic acid—CYP2C9—Metabolism—CAT—psoriasis	8.31e-06	0.000304	CbGpPWpGaD
Mefenamic acid—PTGS2—Disease—CD4—psoriasis	8.03e-06	0.000294	CbGpPWpGaD
Mefenamic acid—CYP2C8—Metabolism—APOE—psoriasis	7.93e-06	0.00029	CbGpPWpGaD
Mefenamic acid—CYP2C8—Metabolism—PPARG—psoriasis	6.91e-06	0.000253	CbGpPWpGaD
Mefenamic acid—CYP2C9—Metabolism—APOE—psoriasis	6.46e-06	0.000236	CbGpPWpGaD
Mefenamic acid—PTGS2—Disease—STAT3—psoriasis	6.22e-06	0.000228	CbGpPWpGaD
Mefenamic acid—CYP2C9—Metabolism—PPARG—psoriasis	5.62e-06	0.000206	CbGpPWpGaD
Mefenamic acid—PTGS2—Disease—IL6—psoriasis	4.35e-06	0.000159	CbGpPWpGaD
